To find clinical trial sponsors before they pick a CRO, you have to work the window between a programme becoming real and the RFP being written. That window is usually a few months wide, it opens on observable public events, and almost nobody works it deliberately.
A COO at a European biometrics CRO described what happens when you miss it: "if we reach out too late, I don't care how well my messages or my colleague's email is or LinkedIn message. If they've already signed for like their phase two study, they're just not going to be interested."
That is the whole problem in one sentence. Outreach quality does not rescue bad timing. A perfect email to a sponsor who signed last month is a worse use of your day than a mediocre email to one who is scoping next quarter.
The window between readout and RFP
Most CRO selection follows a recognisable sequence. A programme produces a result. The company decides to advance it. Money is raised or allocated. People are hired to run it. Vendors are scoped. An RFP goes out.
By the RFP stage, a shortlist usually exists. Someone has had conversations. The document is often written with a preferred vendor's capabilities already in mind. If your first contact is your RFP response, you are competing on price against someone who has been in the room for months.
The events worth working sit two to three steps earlier, when the programme is real but the vendor question is still open.
Five registry events that precede CRO selection
These are all visible in public trial registries. None of them requires private intent data.
| Event | What it signals | Why it matters for timing |
|---|---|---|
| First registration for a company | A programme has become real enough to register | Earliest reliable public marker that a sponsor exists |
| Phase change | A programme advanced, usually after a readout | Scope and budget for the next phase are being decided now |
| Site country added | The study is expanding geographically | Often precedes a need for regional capability the current vendor lacks |
| Recruitment status change | Enrolment opened, paused or completed | A pause signals trouble; completion signals the next study is being planned |
| Principal investigator change | Clinical leadership on the study shifted | Frequently accompanies a broader reassessment of how the programme is run |
None of these is a guarantee. A phase change does not mean a sponsor is unhappy with their current CRO. What it means is that a decision is live somewhere in that organisation, and a well-informed message has somewhere to land.
Three precursors that never appear in a registry
Registry events tell you a programme moved. These tell you it is about to.
CMC and clinical operations hiring. A company posting for a head of clinical operations, a CMC lead or a clinical trial manager is building capacity to run something. Hiring precedes outsourcing decisions more reliably than almost any registry event, because you cannot scope work you have nobody to manage.
Financing. A Series B, a crossover round or a public raise is the budget event. The announcement usually names what the money is for, and if it names a programme you cover, that is a dated, specific reason to write.
S-1 and equivalent filings. For companies approaching public markets, the filing sets out the pipeline, the planned studies and the risk factors in more detail than the company will ever put in a press release. It is the single richest public document about a sponsor's next two years.
A weekly routine for a two-person BD team
The failure mode is not lack of data. It is that nobody has forty minutes on a Monday.
- Twenty minutes on movement. Review the tracked accounts where something changed in the last week: phase transitions, new registrations, status changes, funding. Not the full list, just the deltas.
- Ten minutes on triage. Split them into "write this week" and "note and revisit". Most changes are the second category and that is fine.
- Ten minutes on the write-this-week pile. One message each, anchored to the specific event. Not a sequence. A sequence is what you send when you do not know why you are writing.
- Once a month, review what you dismissed. Sponsors you set aside in March are often the right call in June, and nobody goes back unless it is a scheduled step.
Cytel found account planning ran 30% faster once the research step stopped being a manual exercise. The routine above is the same principle at the territory level: the time saving is real, but the compounding benefit is that a repeatable rhythm actually gets repeated.
See Salesmotion on a real account
Book a 15-minute demo and see how your team saves hours on account research.
The academic sponsor problem
One warning if your territory includes the UK or continental Europe. A large share of registry results there are university hospitals, national health bodies and academic consortia, which mostly do not buy CRO services the way a company does.
Filter the sponsor universe by therapeutic area, phase and modality and most academic centres drop out in one step, because they do not carry a company pipeline. A quick scan of the remaining names handles the rest.
Frequently asked questions
How far ahead can you realistically see? Reliably from first trial registration, and often earlier through financing and hiring signals. Before a company has registered anything, announced funding or posted a role, there is very little public trail, and any vendor claiming otherwise is guessing.
Can you predict when an RFP will be issued? No. We show the events that usually come before one. Predicting the RFP itself would require knowing internal procurement timetables, which is not public information, and a BD team can tell when a tool is pretending.
What about completed trials, do those matter? They matter for understanding a sponsor's history, though for this motion the active and upcoming work is what drives the timing. If historical depth is central to how you qualify, raise it early so we can walk through the coverage on your therapeutic areas.
Is one message really better than a sequence? For this motion, yes. The whole premise is that you have a specific, dated reason to write. A sequence dilutes that into three follow-ups that do not reference anything, which is how a well-timed message turns into ordinary outbound.
If you want to see which of your therapeutic areas actually have movement this quarter, that takes about half an hour on real data rather than a slide. See how it works for CRO business development.
